The aldosterone syntase inhibitor offers hope for the treatment of uncontrolled hypertension

Lorundrostat, a new therapy that blocks the production of aldosterone from the adrenal glands, showed clinically significant and permanent reduction of blood pressure in 1083 patients with uncontrolled or resistant hypertension, in accordance with the results of the currently announced phase test 3.

Data from the start test, announced at 34^th The European meeting on hypertension and cardiovascular protection show that Lorundrostat, aldosterone syntase inhibitor, is a safe and effective treatment of people with uncontrolled or resistant hypertension, showing a coherent reduction of blood pressure in a large and diverse population of patients. This is the largest phase of the third phase of the aldosterone syntase inhibitor for the treatment of hypertension.

The results are the main milestone in the scope of providing the first targeted aldosterone syntase inhibitor for uncontrolled or resistant hypertension, which can benefit to millions of people affected by these conditions.

Dr Manish Saxena, clinical co -director Queen Mary University of London William Harvey Heart Center and a specialist in hypertension at Barts Health Nhs Trust, is the main researcher of the study. He said:

“

”

Hypertension affects 1 in 3 adults around the world and increases the risk of heart disease, heart attack and stroke.

30% of people with hypertension diverged aldosterone, which means that the natural mechanism of controlling aldosterone is disturbed. Increased aldosterone levels can cause hypertension. Lorundrostat has been designed to reduce aldosterone by inhibiting CYP11B2, the enzyme responsible for its production.

Results

The HTN launch study was a global, randomized, double -blind, controlled placebo phase 3 examination, which saved qualifying adult participants who did not achieve the purpose of blood pressure, despite two to five anti -pressure drugs. Launch-HTN reflects the real place for clinicians, using automated measures of office blood pressure (AOBP) and enabling participants to remain on existing medicines.

Lorundrostat 50 mg long ago showed a clinically significant and permanent reduction in spasm blood pressure, with a reduction of 16.9 mmHg in the 6th week (and placebo -9.1 mmhg) and corrected by 19 mmHg in the 12th week (placebo placebo).